Amneal Pharmaceuticals, Inc. announced that their new medication Crexont®, was approved by the Food and Drug Administration.
Crexont is a novel oral formulation of carbidopa-levodopa extended-release capsules. Similar to Amneal’s Rytary, it contains both immediate-release and extended-release elements in the capsule and is designed to increase the length of time that a dose of carbidopa-levodopa is effective, thereby reducing OFF time.
Click here for more information and to read the entire article.
|